Schebitran en es it fr

Schebitran Brand names, Schebitran Analogs

Schebitran Brand Names Mixture

  • No information avaliable

Schebitran Chemical_Formula


Schebitran RX_link

No information avaliable

Schebitran fda sheet

Schebitran msds (material safety sheet)

Schebitran MSDS

Schebitran Synthesis Reference

No information avaliable

Schebitran Molecular Weight

380.657 g/mol

Schebitran Melting Point

No information avaliable

Schebitran H2O Solubility

No information avaliable

Schebitran State


Schebitran LogP


Schebitran Dosage Forms

No information avaliable

Schebitran Indication

Used in the treatment of oedema (including that associated with heart failure) and hypertension.

Schebitran Pharmacology

Trichloromethiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Trichloromethiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomer-ulonephritis, and chronic renal failure. Trichloromethiazide is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Like other thiazides, Trichloromethiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Schebitran Absorption

No information avaliable

Schebitran side effects and Toxicity

Oral Rat LD50 = 5600 mg/kg, oral Mouse LD50 = 2600 mg/kg

Schebitran Patient Information

No information avaliable

Schebitran Organisms Affected

Humans and other mammals